Review
doi: 10.1038/nrc2627.
Parallel progression of primary tumours and metastases
Affiliations
- PMID: 19308069
- DOI: 10.1038/nrc2627
Item in Clipboard
Review
Parallel progression of primary tumours and metastases
Nat Rev Cancer.
2009 Apr.
Abstract
Systemic cancer progression is accounted for in two basic models. The prevailing archetype places the engine of cancer progression within the primary tumour before metastatic dissemination of fully malignant cells. The second posits parallel, independent progression of metastases arising from early disseminated tumour cells. This Perspective draws together data from disease courses, tumour growth rates, autopsy studies, clinical trials and molecular genetic analyses of primary and disseminated tumour cells in support of the parallel progression model. Consideration of this model urges review of current diagnostic and therapeutic routines.
Comment in
-
Parallel progression of tumour and metastases.Nat Rev Cancer. 2010 Feb;10(2):156. doi: 10.1038/nrc2627-c1. Nat Rev Cancer. 2010. PMID: 20094050 No abstract available.
Similar articles
-
Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis.Int J Cancer. 2010 Feb 1;126(3):589-98. doi: 10.1002/ijc.24916. Int J Cancer. 2010. PMID: 19795462 Review.
-
[From single disseminated tumor cells to metastasis insights from molecular genetic analyses of single cells].Verh Dtsch Ges Pathol. 2003;87:158-64. Verh Dtsch Ges Pathol. 2003. PMID: 16888908 German.
-
Selection and adaptation during metastatic cancer progression.Nature. 2013 Sep 19;501(7467):365-72. doi: 10.1038/nature12628. Nature. 2013. PMID: 24048069
-
Using tumour phylogenetics to identify the roots of metastasis in humans.Nat Rev Clin Oncol. 2015 May;12(5):258-72. doi: 10.1038/nrclinonc.2014.238. Epub 2015 Jan 20. Nat Rev Clin Oncol. 2015. PMID: 25601447 Review.
-
Integrated molecular and clinical staging defines the spectrum of metastatic cancer.Nat Rev Clin Oncol. 2019 Sep;16(9):581-588. doi: 10.1038/s41571-019-0220-6. Nat Rev Clin Oncol. 2019. PMID: 31092903 Review.
Cited by
-
The metastasis-promoting roles of tumor-associated immune cells.J Mol Med (Berl). 2013 Apr;91(4):411-29. doi: 10.1007/s00109-013-1021-5. Epub 2013 Mar 21. J Mol Med (Berl). 2013. PMID: 23515621 Free PMC article. Review.
-
A Cross-Sectional Comparison of Druggable Mutations in Primary Tumors, Metastatic Tissue, Circulating Tumor Cells, and Cell-Free Circulating DNA in Patients with Metastatic Breast Cancer: The MIRROR Study Protocol.JMIR Res Protoc. 2016 Aug 16;5(3):e167. doi: 10.2196/resprot.6024. JMIR Res Protoc. 2016. PMID: 27531554 Free PMC article.
-
Melanoma: Molecular genetics, metastasis, targeted therapies, immunotherapies, and therapeutic resistance.Genes Dis. 2022 Apr 27;9(6):1608-1623. doi: 10.1016/j.gendis.2022.04.004. eCollection 2022 Nov. Genes Dis. 2022. PMID: 36157497 Free PMC article. Review.
-
Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer.Br J Cancer. 2013 Jun 25;108(12):2426-32. doi: 10.1038/bjc.2013.265. Epub 2013 Jun 11. Br J Cancer. 2013. PMID: 23756869 Free PMC article. Review.
-
Evaluation of circulating tumor cells as a prognostic biomarker for early recurrence in stage II-III breast cancer patients using CytoSorter® system: a retrospective study.PeerJ. 2021 Apr 29;9:e11366. doi: 10.7717/peerj.11366. eCollection 2021. PeerJ. 2021. PMID: 33987029 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
